Testimony before the FDA’s Pharmacy Compounding Advisory Committee about Hydroxyprogesterone Caproate
In testimony before the FDA’s Pharmacy Compounding Advisory Committee, Public Citizen urged the committee to fully support the FDA’s recommendation to add hydroxyprogesterone caproate for the prevention of preterm birth to the list of drug products that were withdrawn or removed from the market for reasons of safety and effectiveness and therefore may not be compounded under the exemptions provided in FDA regulations. By a vote of 9-0, the committee supported the FDA’s recommendation.